Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

The effect of breakthrough hemolysis on complement factor h and factor I levels in paroxysmal nocturnal hemoglobinuria

Matthew Holt, Daniel Payne, Natalie Fox et al. Nov 03, 2025 pp. 3193-3193 10.1182/blood-2025-3193

Abstract Paroxysmal Nocturnal Hemoglobinuria (PNH) is characterised by chronic complement-mediated hemolysis. The alternative pathway (AP) o...

RUNX1 mutations define a high-risk biological subset of chronic myelomonocytic leukemia and cooperate with ASXL1 mutations to drive leukemic transformation

Roberta S. Azevedo, Sanam Loghavi, Kelly Chien et al. Nov 03, 2025 pp. 3857-3857 10.1182/blood-2025-3857

Abstract Background: RUNX1 mutations (RUNX1mut) are recurrent alterations in chronic myelomonocytic leukemia (CMML) which promote myeloid bia...

Factors associated with achieving complete response in patients older than 65 years diagnosed with diffuse large b-cell lymphoma in first-line therapy. report from a tertiary center in Mexico city

Carla Medrano, Miguel Ramos, Silvia Rivas et al. Nov 03, 2025 pp. 7183-7183 10.1182/blood-2025-7183

Abstract Introduction: The prevalence of diffuse large B-cell lymphoma (DLBCL) in the geriatric population has increased in recent decades....

Outcomes with repeat CAR-t cell therapy: A systematic review and meta-analysis

Hafiz Muhammad Hannan Javed, Fatima Sial, Farooq Ashraf et al. Nov 03, 2025 pp. 7632-7632 10.1182/blood-2025-7632

Abstract Introduction: Chimeric Antigen Receptor (CAR) T-cell therapy has transformed the treatment of relapsed or refractory B-cell maligna...

Role of fludarabine exposure on post-transplant outcomes in high-risk β-thalassemia patients undergoing allogeneic HCT with thiotepa/ fludarabine/ treosulfan conditioning

Rachel Renji, Aswin PAI, Nayanthara Bijukumar et al. Nov 03, 2025 pp. 2419-2419 10.1182/blood-2025-2419

Abstract Fludarabine (Flu) in combination with Treosulfan (Treo) and Thiotepa (Thio) (TFT) has been used as a toxicity-reduced conditioning...

Impact of pulmonary and cardiac comorbidities on cytokine release syndrome incidence in chimeric antigen receptor (CAR) t-treated diffuse large B-cell lymphoma (DLBCL) patients: A real-world data analysis

Heidi Cho, Scott Smith, Darko Dabic et al. Nov 03, 2025 pp. 7673-7673 10.1182/blood-2025-7673

Abstract Background: CAR T-cell therapies using genetically modified autologous T cells targeting CD19 have been approved for third-line the...

Injectable pentosan polysulfate: A novel cause of heparin-induced thrombocytopenia and stroke

Alexandra Rusz, Alex Winter, Dillon Voss et al. Nov 03, 2025 pp. 1339-1339 10.1182/blood-2025-1339

Abstract Introduction: We describe a rare and diagnostically challenging presentation of heparin-induced thrombocytopeni...

A phase 2 open-label study of epeleuton in patients with sickle cell disease

Biree Andemariam, Vivien Sheehan, Fuad El Rassi et al. Nov 03, 2025 pp. 4754-4754 10.1182/blood-2025-4754

Abstract Background and Significance Sickle cell disease (SCD) is a rare inherited blood disorder caused by a single point mutation in the b...

Front-line treatment of Philadelphia negative B-cell acute lymphoblastic leukemia with hypercvad with blinatumomab

Aaron Logan, Mimi Lo, Lloyd Damon et al. Nov 03, 2025 pp. 6861-6861 10.1182/blood-2025-6861

Abstract Introduction: Blinatumomab (Blin), a CD19xCD3 bispecific T-cell engager, is recommended in the consolidation phase of front-line th...

Asciminib pediatric formulation shows a tolerable safety profile in pediatric patients with chronic myeloid leukemia in chronic phase (CML-CP): Second interim analysis from the ASC4KIDS study

Jessica Pollard, Hiroyuki Shimada, Shruti Kapoor et al. Nov 03, 2025 pp. 7312-7312 10.1182/blood-2025-7312

Abstract Introduction: Standard of care tyrosine kinase inhibitors (TKIs) improve the outcomes for children with Philadelphia chromosome–pos...

Neutrophil extracellular traps drive myeloproliferation and immune dysfunction in chronic myelomonocytic leukemia

Saveg Yadav, Callie Brown, Mark Cody et al. Nov 03, 2025 pp. 2057-2057 10.1182/blood-2025-2057

Abstract Background: Chronic myelomonocytic leukemia (CMML) is an aggressive hematologic malignancy characterized by myelodysplastic and mye...

Wstf degradation through nuclear autophagy promotes inflammatory responses in primary myelofibrosis: Implications for XPO1 inhibitor-based therapeutic strategies

Na Xu, Ziyu Wen, Bingyu Lin et al. Nov 03, 2025 pp. 7280-7280 10.1182/blood-2025-7280

Abstract Background: Primary myelofibrosis (PMF) is a chronic myeloproliferative neoplasm characterized by persistent inflammation. Nuclear...

Extracellular vesicle dynamics as biomarkers in sickle cell disease across therapies

Leticia Fernandes, Oshin Sharma, Madeleine Tincher et al. Nov 03, 2025 pp. 6494-6494 10.1182/blood-2025-6494

Abstract Introduction Sickle cell disease (SCD) is characterized by chronic hemolysis and endothelial dysfunction, driving inflammation and...

Bone marrow adipocytes fuel hematopoietic regeneration via fatty acid release

Xiang Gao, Bo Shen Nov 03, 2025 pp. 864-864 10.1182/blood-2025-864

Abstract In adulthood, hematopoietic stem cells (HSCs) reside in the bone marrow niche, where they are maintained by growth factors such as...

Real-world monotherapy and combination usage of mogamulizumab among patients with mycosis fungoides or Sézary syndrome in the United States

Bradley Haverkos, Chunlan Chang, Robert Ristuccia et al. Nov 03, 2025 pp. 4522-4522 10.1182/blood-2025-4522

Abstract Introduction Mogamulizumab is approved in the United States (US) for the treatment of adults with relapsed/refractory (r/r) mycosis...

Synergistic efficacy and preliminary molecular mechanisms of venetoclax combined with microtransplantation in the treatment of elderly patients with Acute Myeloid Leukemia

Yuxian Huang, Yingzhi He, Jiayue Wei et al. Nov 03, 2025 pp. 7794-7794 10.1182/blood-2025-7794

Abstract Background: Elderly patients with acute myeloid leukemia (AML) have poor prognosis, which is attributed to multiple factors includi...

National trends in mortality due to disseminated intravascular coagulation and sepsis: A 21-year analysis of hematologic emergencies in the United States

Sidra Naz, Rushi Shah, Maitri Shah et al. Nov 03, 2025 pp. 3091-3091 10.1182/blood-2025-3091

Abstract Introduction: Disseminated intravascular coagulation (DIC) is a life-threatening coagulopathy frequently associated with sepsis, ma...

Orelabrutinib combined with bendamustine-rituximab or obinutuzumab followed by orelabrutinib maintenance in untreated marginal zone lymphoma (Optimize): A multicenter, single-arm, phase II study

Xuewu Zhang, Yunfei Lv, Xiang Zhang et al. Nov 03, 2025 pp. 3596-3596 10.1182/blood-2025-3596

Abstract Background: The absence of a standard first-line treatment for marginal zone lymphoma (MZL) and the toxicities of existing systemic...

Novel diagnostic and prognostic tools for patients with chronic idiopathic neutropenia: Data on a cohort of 266 patients

Grigorios Tsaknakis, Anna Maria Perantonaki, Stavros Papadakis et al. Nov 03, 2025 pp. 623-623 10.1182/blood-2025-623

Abstract Background: Chronic Idiopathic Neutropenia (CIN) is a neutrophil disorder characterized by the persistent and unexplained reduction...

CD 34 stem cell boost in patients with poor graft function after allogeneic hematopoietic stem cell transplantation: Experience from a tertiary care center

Nada Alshaikh, Mohammed Essa, Bader Alahmari et al. Nov 03, 2025 pp. 7723-7723 10.1182/blood-2025-7723

Abstract Introduction: Poor hematopoietic reconstitution (PHR), in the form of poor graft function (PGF) is a life-threatening complication...

Characteristics and outcome of composite lymphomas: A synthetic cohort approach

Benedikt Pelzer, Sara Jennrich, Tudor-Mihai Magdas et al. Nov 03, 2025 pp. 7098-7098 10.1182/blood-2025-7098

Abstract The coexistence of two distinct lymphoma subtypes within a single patient, either in the same anatomical site (composite lymphoma,...

Real-world selection of fixed-duration versus continuous therapies for treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma

Rebecca Tidswell, Carolyn Owen, Mona Shafey et al. Nov 03, 2025 pp. 4513-4513 10.1182/blood-2025-4513

Abstract Introduction: The therapeutic landscape for treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)...

Dissecting clonal hematopoiesis in diffuse large B-cell lymphoma through multi-compartment genomic profiling

Nawar Maher, Samir Mouhssine, Mohammad Almasri et al. Nov 03, 2025 pp. 3537-3537 10.1182/blood-2025-3537

Abstract Background: Clonal hematopoiesis (CH) in diffuse large B-cell lymphoma (DLBCL) has been investigated in a limited number of studies...

Evaluating the efficacy of montelukast in reducing the incidence and severity of monoclonal antibodies-associated infusion reactions (Phase II Study)

Omar Mahmood, Christopher Leung, Palak Tohan et al. Nov 03, 2025 pp. 6196-6196 10.1182/blood-2025-6196

Abstract Introduction Monoclonal antibodies (MABs) and antibody-drug conjugates (ADCs) are increasingly utilized in hematology-oncology. How...

Real-world assessment of prophylactic anakinra on neurotoxicity after CD19 CAR T-cell therapy in R/R B-cell lymphoma: An inverse probability of treatment weighting analysis

Neela Easwar, Mia Andreoli, Herman Van Besien et al. Nov 03, 2025 pp. 712-712 10.1182/blood-2025-712

Abstract Introduction Immune effector cell-associated neurotoxicity syndrome (ICANS) is a common toxicity of CD19 CAR T-cell therapy (CAR T)...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page